NCT05561816

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Opened, Multicenter, Randomized, in Parallel Groups Comparative Study to Assess Efficacy and Safety of Dioxidin®, Solution for Topical and External Application 0.025% (Valenta Farm, Russia) and Miramistin®, Solution for Topical Application 0.01% (Infamed K LLC, Russia) in Treatment of Superficial Pyoderma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study is aimed to: * evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, * evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

Conditions

• Pyoderma

Interventions

Type	Name	Description
DRUG	Hydroxymethylquinoxalindioxyde	Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
DRUG	Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium	Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)

Timeline

• Start date: 2022-07-19
• Primary completion: 2022-11-28
• Completion: 2022-12-20
• First posted: 2022-09-30
• Last updated: 2023-10-10

Locations

10 sites across 1 country: Russia